Clinical Trials Sponsored by Alnylam Pharmaceuticals

Total 19749 results

Alnylam Pharmaceuticals

Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)

Transthyretin-Mediated Amyloidosis | ATTR Amyloidosis

Israel, Italy, Netherlands, Spain, United States, France, Denmark, Germany, Portugal, Brazil, Taiwan
Alnylam Pharmaceuticals

Active, not recruiting

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria

United States, France, United Kingdom, Israel, Germany
Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

Acute Hepatic Porphyria
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

Hypertension

United States, Canada, United Kingdom, Puerto Rico, Ukraine
Alnylam Pharmaceuticals

Completed

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Amyloidosis, Familial | Transthyretin Amyloidosis

France, Germany, Italy, Portugal, Spain, Sweden, United Kingdom
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Amyloidosis

United States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom, Germany, France, Korea, Republic of, Brazil, Mexico, Turkey
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Alnylam Pharmaceuticals

Completed

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

United States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa
Alnylam Pharmaceuticals

Terminated

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

United Kingdom
Alnylam Pharmaceuticals

Terminated

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

Acute Hepatic Porphyria | Acute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP) | Hepatic Porphyrias | Porphyria Acute

United States
Alnylam Pharmaceuticals

Terminated

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Antitrypsin Deficiency Liver Disease

United Kingdom
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
Alnylam Pharmaceuticals

Completed

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Acute Intermittent Porphyria

United States, United Kingdom, Sweden
Alnylam Pharmaceuticals

Completed

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Solid Tumors

United States, Spain
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Austin Neuromuscular Center
Alnylam Pharmaceuticals

Recruiting

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Polyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR Amyloidosis

United States
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Alnylam Pharmaceuticals
The Medicines Company

Completed

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Hypercholesterolemia

United Kingdom
Yale University
Alnylam Pharmaceuticals Inc

Not yet recruiting

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Transthyretin Amyloidosis

United States
CENTOGENE GmbH Rostock
Alnylam Pharmaceuticals

Recruiting

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects (TRAMmoniTTR)

Cardiomyopathies | Polyneuropathies | Transthyretin Amyloidosis | Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Germany, Austria, Switzerland
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Completed

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, New Zealand, Thailand
Charite University, Berlin, Germany
Alnylam Pharmaceuticals

Not yet recruiting

Lumasiran in Hyperoxalaemic Patients on Haemodialysis (LHOxH)

Cardiovascular Disease | Cardiovascular Risk Factor | Haemodialysis | Chronic Kidney Disease Requiring Chronic Dialysis | Hyperoxalemia
Brii Biosciences Limited
Alnylam Pharmaceuticals; Vir Biotechnology, Inc.

Completed

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Hepatitis B, Chronic

China
Mario Negri Institute for Pharmacological Research
Alnylam Pharmaceuticals

Withdrawn

Eculizumab to Cemdisiran Switch in aHUS (DANCE)

Atypical Hemolytic Uremic Syndrome

Italy
RwHealth
Northern Care Alliance NHS Foundation Trust; Alnylam Pharmaceuticals

Not yet recruiting

RWE-based Treatment Patterns and Outcomes in CIDP

Hereditary Amyloidosis | Guillain-Barre Syndrome | Chronic Inflammatory Demyelinating Polyneuropathy

United Kingdom
Massachusetts General Hospital
Pfizer; Akcea Therapeutics; Alnylam Pharmaceuticals; Eidos Therapeutics, a BridgeBio...

Recruiting

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF (TTRinHFpEF)

Heart Failure | Amyloidosis | Heart Failure, Diastolic | Transthyretin Amyloidosis

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada

Clinical Trials Sponsored by Alnylam Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations